Clinical implication of 14-3-3 epsilon expression in gastric cancer

World Journal of Gastroenterology

Volumn 18, Issue 13, 2012, Pages 1531-1537

  Leal, Mariana Ferreira ^a   Calcagno, Danielle Queiroz ^a   Demachki, Sâmia ^b   Assumpção, Paulo Pimentel ^b   Chammas, Roger ^c   Burbano, Rommel Rodríguez ^b   Smith, Marília de Arruda Cardoso ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

14 3 3 epsilon; Gastric cancer; Gene expression; Protein expression; YWHAE

Indexed keywords

MESSENGER RNA; PROTEIN 14 3 3; PROTEIN 14 3 3EPSILON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; STOMACH CANCER;

EID: 84859314329     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i13.1531     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362
3. Shah MA, Ajani JA. Gastric cancer--an enigmatic and heterogeneous disease. JAMA 2010; 303: 1753-1754
4. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, Bazan V, Russo A. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 2006; 17 Suppl 7: vii97-vi102
5. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett 2008; 266: 99-115
6. Khayat AS, Guimarães AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpção PP, Demachki S, Smith MA, Burbano RR. Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol 2009; 9: 55
7. Leal MF, Martins do Nascimento JL, da Silva CE, Vita Lamarão MF, Calcagno DQ, Khayat AS, Assumpção PP, Cabral IR, de Arruda Cardoso Smith M, Burbano RR. Establishment and conventional cytogenetic characterization of three gastric cancer cell lines. Cancer Genet Cytogenet 2009; 195: 85-91
8. Ribeiro HF, Alcântara DF, Matos LA, Sousa JM, Leal MF, Smith MA, Burbano RR, Bahia MO. Cytogenetic characterization and evaluation of c-MYC gene amplification in PG100, a new Brazilian gastric cancer cell line. Braz J Med Biol Res 2010; 43: 717-721
9. Leal MF, Calcagno DQ, Borges da Costa Jde F, Silva TC, Khayat AS, Chen ES, Assumpção PP, de Arruda Cardoso Smith M, Burbano RR. MYC, TP53, and chromosome 17 copy-number alterations in multiple gastric cancer cell lines and in their parental primary tumors. J Biomed Biotechnol 2011; 2011: 631268
10. Szymańska K, Hainaut P. TP53 and mutations in human cancer. Acta Biochim Pol 2003; 50: 231-238
11. Aitken A. 14-3-3 proteins: a historic overview. Semin Cancer Biol 2006; 16: 162-172
12. Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000; 40: 617-647
13. van Hemert MJ, Steensma HY, van Heusden GP. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 2001; 23: 936-946
14. Pozuelo Rubio M, Geraghty KM, Wong BH, Wood NT, Campbell DG, Morrice N, Mackintosh C. 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J 2004; 379: 395-408
15. Satoh J, Nanri Y, Yamamura T. Rapid identification of 14-3-3-binding proteins by protein microarray analysis. J Neurosci Methods 2006; 152: 278-288
16. Rajagopalan S, Sade RS, Townsley FM, Fersht AR. Mechanistic differences in the transcriptional activation of p53 by 14-3-3 isoforms. Nucleic Acids Res 2010; 38: 893-906
17. Tzivion G, Avruch J. 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 2002; 277: 3061-3064
18. Yaffe MB. How do 14-3-3 proteins work?--Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett 2002; 513: 53-57
19. Aitken A. Functional specificity in 14-3-3 isoform interactions through dimer formation and phosphorylation. Chromosome location of mammalian isoforms and variants. Plant Mol Biol 2002; 50: 993-1010
20. Jones DH, Ley S, Aitken A. Isoforms of 14-3-3 protein can form homo-and heterodimers in vivo and in vitro: implications for function as adapter proteins. FEBS Lett 1995; 368: 55-58
21. Konishi H, Nakagawa T, Harano T, Mizuno K, Saito H, Masuda A, Matsuda H, Osada H, Takahashi T. Identification of frequent G(2) checkpoint impairment and a homozygous deletion of 14-3-3epsilon at 17p13.3 in small cell lung cancers. Cancer Res 2002; 62: 271-276
22. Che XH, Chen H, Xu ZM, Shang C, Sun KL, Fu WN. 14-3-3epsilon contributes to tumour suppression in laryngeal carcinoma by affecting apoptosis and invasion. BMC Cancer 2010; 10: 306
23. Cvekl A, Zavadil J, Birshtein BK, Grotzer MA, Cvekl A. Analysis of transcripts from 17p13.3 in medulloblastoma suggests ROX/MNT as a potential tumour suppressor gene. Eur J Cancer 2004; 40: 2525-2532
24. Liang S, Xu Y, Shen G, Liu Q, Zhao X, Xu Z, Xie X, Gong F, Li R, Wei Y. Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis 2009; 30: 4152-4162
25. Cao L, Cao W, Zhang W, Lin H, Yang X, Zhen H, Cheng J, Dong W, Huo J, Zhang X. Identification of 14-3-3 protein isoforms in human astrocytoma by immunohistochemistry. Neurosci Lett 2008; 432: 94-99
26. Liu Y, Tian RF, Li YM, Liu WP, Cao L, Yang XL, Cao WD, Zhang X. The expression of seven 14-3-3 isoforms in human meningioma. Brain Res 2010; 1336: 98-102
27. Lukashova-v Zangen I, Kneitz S, Monoranu CM, Rutkowski S, Hinkes B, Vince GH, Huang B, Roggendorf W. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol 2007; 113: 325-337
28. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49
29. Sobin LH, Wittekind CH. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss, 2002
30. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45
31. Kokkola A, Sipponen P. Gastric carcinoma in young adults. Hepatogastroenterology 2001; 48: 1552-1555
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
33. Kumagai A, Yakowec PS, Dunphy WG. 14-3-3 proteins act as negative regulators of the mitotic inducer Cdc25 in Xenopus egg extracts. Mol Biol Cell 1998; 9: 345-354
34. Kumagai A, Dunphy WG. Binding of 14-3-3 proteins and nuclear export control the intracellular localization of the mitotic inducer Cdc25. Genes Dev 1999; 13: 1067-1072
35. Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, Tahara E. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res 1997; 88: 947-952
36. Zhang XM, Yao GY, Zhang BY, Wang LL, Zhao M. [Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]. Zhonghua Yixue Yichuanxue Zazhi 2009; 26: 288-292
37. Takahashi H, Murai Y, Tsuneyama K, Nomoto K, Okada E, Fujita H, Takano Y. High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis. Appl Immunohistochem Mol Morphol 2007; 15: 267-272
38. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-6740
39. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ 2004; 327-349
40. Smith MG, Hold GL, Tahara E, El-Omar EM. Cellular and molecular aspects of gastric cancer. World J Gastroenterol 2006; 12: 2979-2990
41. Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR. MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol 2008; 14: 5962-5968
42. Kozma L, Kiss I, Hajdú J, Szentkereszty Z, Szakáll S, Ember I. C-myc amplification and cluster analysis in human gastric carcinoma. Anticancer Res 2001; 21: 707-710
43. Yang GF, Deng CS, Xiong YY, Gong LL, Wang BC, Luo J. Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: association with Helicobactor pylori cagA (+) infection. World J Gastroenterol 2004; 10: 491-496
44. Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M. C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res 2006; 26: 2909-2914
45. Calcagno DQ, Leal MF, Taken SS, Assumpção PP, Demachki S, Smith Mde A, Burbano RR. Aneuploidy of chromosome and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. Anticancer Res 2005; 25: 4069-4074
46. Xing X, Chen J, Chen M. Expression of CDC25 phosphatases in human gastric cancer. Dig Dis Sci 2008; 53: 949-953
47. Prochownik EV, Li Y. The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle 2007; 6: 1024-1029
48. Carvalho R, Milne AN, van Rees BP, Caspers E, Cirnes L, Figueiredo C, Offerhaus GJ, Weterman MA. Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age. J Pathol 2004; 204: 75-83
49. Milne AN, Carvalho R, Morsink FM, Musler AR, de Leng WW, Ristimäki A, Offerhaus GJ. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol 2006; 19: 564-572
50. Milne AN, Sitarz R, Carvalho R, Carneiro F, Offerhaus GJ. Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. Curr Mol Med 2007; 7: 15-28